NCT00706706 - Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Sunitinib Malate (SU011248)

Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.

Trial Locations (11)

Pfizer Investigational Site, Beijing

Pfizer Investigational Site, Beijing

Pfizer Investigational Site, Beijing

Pfizer Investigational Site, Shanghai

Pfizer Investigational Site, Shanghai

Pfizer Investigational Site, Nanjing

Pfizer Investigational Site, Tianjin

Pfizer Investigational Site, Chongqing

Pfizer Investigational Site, Wuhan

Pfizer Investigational Site, Guangzhou

Pfizer Investigational Site, Xi'an